Expanding Access to Biosimilars Has Bipartisan Support, But Movement on Legislation Hangs in the Bal

Advocates fear three bipartisan bills on lower-cost versions of biologic drugs will get caught up in H.R. 3 negotiations.

Click here to read the full article.